TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06331156

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HRV PCV-free
Description: 2 doses of HRV PCV-free vaccine are administered orally at Month 0.5 and Month 1.5 (Co-administration Group) and at Day 1 and Month 1 (Staggered Group), according to the immunization schedule for HRV vaccine licensed outside of China. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: HRV PCV-free
Description: 2 doses of HRV PCV-free vaccine are administered orally at Month 0.5 and Month 1.5 (Co-administration Group) and at Day 1 and Month 1 (Staggered Group), according to the immunization schedule for HRV vaccine licensed outside of China. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IPV
Description: 3 doses of IPV vaccine are administered intramuscularly at Month 0.5, Month 1.5 and Month 2.5 (Co-administration Group and Staggered Group), according to the recommended schedule for vaccination against poliovirus in China.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: IPV
Description: 3 doses of IPV vaccine are administered intramuscularly at Month 0.5, Month 1.5 and Month 2.5 (Co-administration Group and Staggered Group), according to the recommended schedule for vaccination against poliovirus in China.
Study: NCT06635434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AR Pain assessment
Description: Age-stratified (age 7-11 and age 12-17 years old) augmented reality app to evaluate for pain and opioid-related adverse events with equivalent English and Spanish text, audio, and narration
Study: NCT05294484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indapamide 1.5 MG SR
Description: the effect of genetic variation of UGT2B7 on human response to treatment with indapamide and its correlation with pharmacokinetic parameters in Egyptian subjects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indapamide 1.5 MG SR
Description: the effect of genetic variation of UGT2B7 on human response to treatment with indapamide and its correlation with pharmacokinetic parameters in Egyptian subjects
Study: NCT05003973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based anti-resistance exercise
Description: It is a 12-week, middle-level, home-based, anti-resistance exercise. Exercise was recommended 1-2 times per day for 15-20 mins per session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: usually care
Description: The leaflet of the lymphedema self-care, including skin care and manual lymphatic drainage

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: usually care
Description: The leaflet of the lymphedema self-care, including skin care and manual lymphatic drainage
Study: NCT06314854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Running water sound
Description: Running water sound for experimental group Standard care for control group
Study: NCT05252494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: animal assisted therapy
Description: In the intervention group, the child will be given to the mother's lap just before the invasive procedure. During the process, the aquarium with the fish will be placed on a shelf at a distance of about 50-60 cm, at an angle that the child can see. The camera on which the blood collection will be recorded will be placed on a tripod and placed on another shelf in such a way that the child can be seen completely. A video recording will be started 1 minute before the procedure, a pulse oximeter device will be attached to the child immediately after the child is seated on his mother's lap, physiological parameters, pain scores and stress will be determined. During the procedure, children's physiological measurements pain score and stress will be re-evaluated after the needle is inserted into the site. After the procedure, children's physiological measurements pain score and stress will be re-evaluated 1 minute after the needle is removed from the injection site
Study: NCT05936619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mind Extender (MindEx)
Description: NeuroPort Multi-Port Arrays allow for the local recording of cerebral cortex. The Mind Extender (MindEx) system is primarily composed of two NeuroPort Multi-Port Arrays. Each Multi-Port device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D), and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array. The four arrays of the two Multi-Port device will be implanted into prefrontal cortex, premotor cortex, primary motor cortex, and posterior parietal cortex.
Study: NCT04476901

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic human mesenchymal stem cells (hMSCs)
Description: allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic human mesenchymal stem cells (hMSCs)
Description: allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic human mesenchymal stem cells (hMSCs)
Description: allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).
Study: NCT05239247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mckenzie extension exercise
Description: Hot pack applied on lumbar region for (ten minute). Mckenzie extension exercise performed 02 sets of 05 repetitions with 45 second hold and 15 sec rest between each set once a day.~TENS is applied on lumbar region for (ten minutes).
Study: NCT04476901

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)
Study: NCT05533827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music
Study: NCT04476901

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)
Study: NCT06447155

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bolus feeding
Description: The babies fed with bolus feeding during TH composed this group

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Continuous feeding
Description: The babies fed with continuous feeding during TH composed this group

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The babies who were not fed during TH composed this group
Study: NCT04959227

Intervention type: OTHER
Intervention: Sema activity
Description: sema activity 3 days a week for at least a year
Study: NCT05533827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Description: Virtual reality glasses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Description: Virtual reality glasses
Study: NCT05239247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eldoa stretch technique
Description: Hot pack applied on lumbar region for (ten minute). Eldoa stretch performed 02 sets of 05 repetitions with 45 second hold and 15 second rest between each set once a day.~TENS is applied on lumbar region for (ten minutes).
Study: NCT05533827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Description: Virtual reality glasses
Study: NCT04040608

Intervention type: OTHER
Intervention: Influence of screen sizes on responses to visual analog scales of stress
Description: An open questionnaire will be created by the Clinical Research Direction. The questionnaire will be opened by the examinator who will fulfill the anonymized identification of participants and the type of screens. In a dedicated room at the LaPSCo, the participants will answer the same VAS on four different sizes/types of screens (24-inch screen, laptop, tablet, smartphone) and on paper. Saliva will be collected after answering questionnaires. Heart rate variability and skin conductance will be measured with the use of a wrist watch during 15 minutes, from the entrance in the room to the completion of questionnaires.~The participant will undergo the same examination within a week (15 minutes).
Study: NCT05774015

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium Oxide tablet 500 mg
Description: To supplement T2DM with Mg oxide tablets (500 mg total, 302 mg elemental) regardless on their magnesium level

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Oxide tablet 500 mg
Description: To supplement T2DM with Mg oxide tablets (500 mg total, 302 mg elemental) regardless on their magnesium level
Study: NCT05908357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: Use of the exergame XboX 360 series with kinect sensor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Booklet
Description: Use of the booklet with instructions of exercises to be done at home with tele-health through whatsapp app.
Study: NCT06324318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting in 2 Worlds (P2W)
Description: P2W is a culturally-adapted parenting intervention designed specifically for urban American Indian families. It is a 10-week, 10-lesson manualized curriculum with accompanying videos, designed to be facilitated by American Indians from the local communities. The workshop lessons cover topics like the identification of family values, culturally influenced child rearing values and traditions, sources of support for parents, and ways to improve parenting skills to communicate with, monitor, and guide adolescents to avoid substance use, unprotected sex and other risk behaviors
Study: NCT06091631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate vaporization
Description: pre-opeative magnesium sulfate vaporization
Study: NCT06324318

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Families in 2 Worlds (HF2W)
Description: HF2W is a 10-week informational family health program. The workshop lessons cover topics such as oral health, CPR and first aid, dating safety, and teen mental health.
Study: NCT06086392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the supraclavicular brachial plexus block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1mg/kg Dexamethasone
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the supraclavicular brachial plexus block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05mg/kg Dexamethasone
Description: administration of 0.5ml/kg of 0,2% ropivacaine with 0.05mg/kg Dexamethasone for the supraclavicular brachial plexus block
Study: NCT05476952

Intervention type: PROCEDURE
Intervention: he patients who are administered rocuronium according to LBW were categorized as LBW, and The group number for those administer according to TBW was categorized as K.
Description: Patients will be divided equally and validly by the one who will be placed in opaque sealed envelopes on a self-paid basis. One group will be given 0.6 mg/kg rocuronium on an LBW basis (Curon ® 50 mg/5 mL \[Mustafa Nevzat, Istanbul, Turkey\]), and the other group will be given 0.6 mg/kg rocuronium on a TBW basis.

Intervention type: PROCEDURE
Intervention: he patients who are administered rocuronium according to LBW were categorized as LBW, and The group number for those administer according to TBW was categorized as K.
Description: Patients will be divided equally and validly by the one who will be placed in opaque sealed envelopes on a self-paid basis. One group will be given 0.6 mg/kg rocuronium on an LBW basis (Curon ® 50 mg/5 mL \[Mustafa Nevzat, Istanbul, Turkey\]), and the other group will be given 0.6 mg/kg rocuronium on a TBW basis.

Intervention type: PROCEDURE
Intervention: he patients who are administered rocuronium according to LBW were categorized as LBW, and The group number for those administer according to TBW was categorized as K.
Description: Patients will be divided equally and validly by the one who will be placed in opaque sealed envelopes on a self-paid basis. One group will be given 0.6 mg/kg rocuronium on an LBW basis (Curon ® 50 mg/5 mL \[Mustafa Nevzat, Istanbul, Turkey\]), and the other group will be given 0.6 mg/kg rocuronium on a TBW basis.
Study: NCT06123741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental Guidance
Description: Parents get guidance for children's positive behaviour support by using parts of Self-Help Program on the MentalHub.fi (in Finnish: Mielenterveystalo.fi) website regarding children's challenging behaviour (in Finnish: Lasten haastavan käytöksen omahoito-ohjelma) .

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental Guidance
Description: Parents get guidance for children's positive behaviour support by using parts of Self-Help Program on the MentalHub.fi (in Finnish: Mielenterveystalo.fi) website regarding children's challenging behaviour (in Finnish: Lasten haastavan käytöksen omahoito-ohjelma) .

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Game
Description: Virtual reality game for rehabilitation of attention, activity control and executive functions by using the virtual environment that corresponds to the typical everyday situations at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Game
Description: Virtual reality game for rehabilitation of attention, activity control and executive functions by using the virtual environment that corresponds to the typical everyday situations at home.
Study: NCT05458843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid replacement
Description: Participants will drink Gatorade Zero ad libitum, up to 1 cup every 15 minutes.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No fluid replacement
Description: Participants will not be permitted to drink.
Study: NCT06354595

Intervention type: DEVICE
Group type: OTHER
Intervention: Multidimensional Rehabilitation in the Metaverse
Description: Using the multidimensional rehabilitation space in the metaverse, evaluate the platform after use.
Study: NCT06404333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHILD-IVITAB
Description: Ivermectin (200 µg/kg) oro-dispersible minitablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHILD-IVITAB
Description: Ivermectin (400 µg/kg) oro-dispersible minitablets
Study: NCT05033184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Action Planning Exercise
Description: The Brief Action Planning exercise is a previously developed goal-setting exercise which has been designed to incorporate aspects of motivational interviewing such as compassion, acceptance, evocation, and partnership. It is a tool that allows participants to identify an aspect of their life they would like to improve upon and guides them through the process of making a specific, measurable, achievable, realistic, and timely (SMART) goal. It also assesses their confidence in achieving this goal so as to assist with making alternative plans if confidence is low.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal Setting Exercise
Description: The Goal Setting exercise allows participants to identify an aspect of their life they would like to improve upon without incorporating aspects of motivational interviewing components or providing any guidance on how to set this goal.
Study: NCT04817475

Intervention type: OTHER
Intervention: Point-of-care ultrasound with tele-supervision
Description: Point-of-care ultrasound of patients with a out-of-hospital cardiac arrest will be performed with tele-supervision.
Study: NCT04394689

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles Rubella Vaccine (MRV-SC)
Description: One dose as subcutaneous injection of a WHO prequalified MR vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRV-MNP
Description: One standard dose of Measles and Rubella vaccine delivered intradermally as a dissolving microneedle patch
Study: NCT03494335

Intervention type: OTHER
Intervention: Online surveys
Description: The investigators are recruiting health care providers for these surveys that are involved in or use imaging.
Study: NCT04394689

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PLA-MNP
Description: One placebo dose of a dissolving microneedle patch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLA-SC
Description: Placebo saline as subcutaneous injection
Study: NCT04994704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propfol group
Description: Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil under target controlled infusion (TCI) model.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam group
Description: Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h for induction, and maintained at 0.5-1.5 mg/kg/h and remifentanil under TCI model.
Study: NCT04477525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Erector Spinae Plane (ESP) Nerve Block
Description: The planned intervention is a bilateral erector spinae nerve block for patients undergoing bariatric surgery. This intervention will be performed in the PACU for patients with an NRS pain score \>5. All eligible candidates who have consented for this study will be present in the PACU, have all standard ASA monitoring placed. The patient will then be placed in a sitting position. The patient will then be prepped with chlorhexidine in the thoracic region and draped in a sterile fashion. The ultrasound will be brought in over the patient and the T7 Transverse Processes (TP) will be identified. An echogenic needle will be placed under direct ultrasound guidance on the TP. Then, 20 cc of 0.25% bupivacaine will be injected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Injection
Description: 20 cc of 0.25% bupivacaine will be injected
Study: NCT06507332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg
Description: to assess and compare the efficacy of Combination of letrozole and clomiphene citrate versus letrozole alone for ovulation induction in women with polycystic ovary syndrome (PCOS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg
Description: to assess and compare the efficacy of Combination of letrozole and clomiphene citrate versus letrozole alone for ovulation induction in women with polycystic ovary syndrome (PCOS)
Study: NCT06231641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lemborexant 5 MG [Dayvigo]
Description: Lemborexant 5 mg will be taken orally once per day just prior to initiating laboratory-supervised daytime sleep episodes, for three consecutive days, within a few minutes before going to bed, with at least seven hours remaining before the planned time of awakening.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo will be taken orally once per day just prior to initiating laboratory-supervised daytime sleep episodes, for three consecutive days, within a few minutes before going to bed, with at least seven hours remaining before the planned time of awakening.
Study: NCT06405685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab 400 mg will be administered on Day 1, 8, 15 of a 28-day cycle by intravenous (IV) administration up to 6 cycles. Imaging (CT or MRI) and tumor markers (such as CA19-9) will be assessed every two cycles of the conversion therapy, until met the criteria of resection and underwent surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG
Description: Patients will receive AG as conversion therapy up to 6 months. Gemcitabine 1000 mg/m\^2 will be administered on Day 1, 8, 15 of a 28-day cycle. nab-Paclitaxel 125 mg/m\^2 will be administered on Day 1, 8, 15 of a 28-day cycle by intravenous (IV) administration up to 6 cycles. Imaging (CT or MRI) and tumor markers (such as CA19-9) will be assessed every two cycles of the conversion therapy, until met the criteria of resection and underwent surgery.
Study: NCT05378776

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucrose
Description: The experimental arm will receive 1.5 ml/kg of the sucrose solution at triage (once). The composition of the homemade sucrose solution used in our emergency department is 3.5 g of table sugar (sucrose) mixed with 10 ml of water. For this double-blind study, we replaced water with diluted juice (see standard arm description) to obtain a solution with the same appearance as the standard arm. With the idea of correcting ketosis, we chose to provide the same amount of sugar as we do in hypoglycemia (0.4-0.5 g/kg of dextrose) to participants in the intervention group, which represents 1.5 ml/kg of the sucrose solution containing 0.4 g of sucrose/mL for a total of 0.6 g/kg of sucrose.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard rehydration solution
Description: This group will receive 1.5 mL/kg of diluted juice composed of juice (apple or orange) and water in equal proportion once at triage. This solution contains 0.05 g/ml of sucrose for a total of 0.075 g/kg of sucrose (eight times less than the intervention arm).
Study: NCT04959604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG-marking endoscopically
Description: Preoperatively the participants will receive an endoscopic marking at four points around the tumour with the fluorescent dye indocyanine green.